Renal Cell Carcinoma: Clinical Trials

262 completed, 97 terminated, 94 unknown, 79 recruiting. 231 Phase 2, 212 Phase 1, 85 Not applicable, 35 Phase 3, 10 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	231	Completed 74, Terminated 49, Recruiting 32, Unknown 32, Active not recruiting 25, Withdrawn 14, Not yet recruiting 4, Suspended 1
Phase 1	212	Completed 84, Terminated 45, Unknown 26, Active not recruiting 25, Recruiting 23, Not yet recruiting 5, Withdrawn 4
Not applicable	85	Completed 27, Unknown 23, Recruiting 11, Terminated 10, Active not recruiting 5, Not yet recruiting 4, Withdrawn 4, Enrolling by invitation 1
Phase 3	35	Completed 18, Active not recruiting 5, Recruiting 5, Terminated 4, Withdrawn 2, Unknown 1
Early Phase 1	10	Completed 4, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Suspended 1, Unknown 1, Withdrawn 1
Phase 4	7	Completed 3, Unknown 2, Recruiting 1, Terminated 1

Follow Renal Cell Carcinoma: new trials by email Literature Review of Renal Cell Carcinoma trials Research Report on Renal Cell Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
68Ga- and 18F-CAIX PET Imaging Study 68Ga-CAIX PET/CT, 18F-CAIX - Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma	Early Phase 1	Not yet recruiting	Peking University First Hospital	100	2026-10-01	2026-10-15
A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer	Phase 4	Recruiting	Memorial Sloan Kettering Cancer Center	40	2026-09-24	2026-10-16
Plasma DNA Methylation for Preoperative Classification of Renal Masses Renal Cell Carcinoma, Benign Renal Mass		Recruiting	RenJi Hospital	240	2026-09-01	2026-10-15
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma Personalized Neoantigen Polyepitope Peptide Vaccine - Renal Cell Carcinoma, Advanced	Phase 1	Not yet recruiting	Jian Lin	8	2026-09-01	2026-07-07
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy Donor Radical and Partial Nephrectomy, Kidney Transplantation, Laparoscopic Radical Nephrectomy - Renal Cell Carcinoma	Not applicable	Not yet recruiting	Case Comprehensive Cancer Center	5	2026-09-01	2026-08-06
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma	Phase 1	Recruiting	Canadian Cancer Trials Group	30	2026-08-30	2026-10-16
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer Proteomic profiling of urinary EVs, Blood sample collection - Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma		Not yet recruiting	Mayo Clinic	300	2026-07-15	2026-02-27
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) Total consolidative MPDT - Renal Cell Carcinoma	Not applicable	Recruiting	Abramson Cancer Center at Penn Medicine	23	2026-06-12	2026-10-08
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer	Phase 1	Recruiting	Huahui Health	299	2026-06-11	2026-08-21
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma	Phase 2	Not yet recruiting	Vall d'Hebron Institute of Oncology	150	2026-06-01	2026-05-20
Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma Intensified Monitoring of Pharmacology - Renal Cell Carcinoma	Not applicable	Recruiting	Centro di Riferimento Oncologico - Aviano	216	2026-05-19	2026-09-04
Identification and Description of Patients With High-risk Non Metastatic RCC Cohort 1, Cohort 2, Cohort 3 - Renal Cell Carcinoma		Recruiting	University Hospital, Bordeaux	6109	2026-04-17	2026-08-07
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer	Phase 2	Recruiting	Dana-Farber Cancer Institute	32	2026-03-09	2026-03-20
A Novel Haemostatic Agent for Robotic Partial Nephrectomy PuraBond - Kidney Cancer, Renal Cell Carcinoma	Not applicable	Withdrawn	The Royal Wolverhampton Hospitals NHS Trust		2026-03-01	2026-03-13
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986506, Pumitamig, Ipilimumab - Renal Cell Carcinoma	Phase 1	Recruiting	Bristol-Myers Squibb	281	2026-01-15	2026-08-11
Retifanlimab and Ruxolitinib In Solid Malignancies Ruxolitinib, Retifanlimab - Non Small Cell Lung Carcinoma, Renal Cell Carcinoma	Phase 1 / Phase 2	Recruiting	University of California, San Diego	40	2026-01-08	2026-01-13
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma	Phase 1	Not yet recruiting	AccSalus Biosciences, Inc.	40	2026-01-01	2025-11-28
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma Imaging-clinical multimodal prognostic modeling - Renal Cell Carcinoma, Kidney Neoplasms		Active not recruiting	Tianjin Medical University Second Hospital	406	2026-01-01	2026-07-13
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma 82-Rb injection - Renal Cell Carcinoma	Phase 2	Not yet recruiting	Assistance Publique - Hôpitaux de Paris	50	2026-01-01	2026-01-16
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma	Phase 1	Recruiting	Neomorph, Inc	30	2025-12-19	2026-10-05

Showing 20 of 640. Sign in to see all of them.

Narrower conditions

Carcinoma, Renal Cell (640)  ·  Kidney Neoplasms (113)  ·  Melanoma (112)  ·  Carcinoma, Non-Small-Cell Lung (102)  ·  Colorectal Neoplasms (61)  ·  Carcinoma, Hepatocellular (53)  ·  Squamous Cell Carcinoma of Head and Neck (52)  ·  Neoplasm Metastasis (51)  ·  Neoplasms (49)  ·  Carcinoma, Transitional Cell (48)  ·  Ovarian Neoplasms (48)  ·  Stomach Neoplasms (45)  ·  Breast Neoplasms (44)  ·  Uterine Cervical Neoplasms (41)  ·  Pancreatic Neoplasms (37)

Broader conditions

Female Urogenital Diseases (640)  ·  Female Urogenital Diseases and Pregnancy Complications (640)  ·  Male Urogenital Diseases (640)  ·  Urogenital Diseases (640)  ·  Neoplasms, Glandular and Epithelial (638)  ·  Urologic Diseases (638)  ·  Neoplasms by Histologic Type (637)  ·  Neoplasms by Site (637)  ·  Adenocarcinoma (636)  ·  Kidney Diseases (634)  ·  Urologic Neoplasms (634)  ·  Urogenital Neoplasms (633)  ·  Carcinoma (627)  ·  Neoplasms (591)  ·  Kidney Neoplasms (527)

Interventions

Nivolumab (57)  ·  pembrolizumab (55)  ·  Sunitinib (38)  ·  Bevacizumab (26)  ·  cabozantinib (26)  ·  Axitinib (25)  ·  Ipilimumab (24)  ·  Everolimus (23)  ·  atezolizumab (16)  ·  lenvatinib (14)  ·  Radiosurgery (13)  ·  Sorafenib (11)  ·  pazopanib (11)  ·  Magnetic Resonance Spectroscopy (10)  ·  avelumab (10)

Sponsors

Pfizer (22)  ·  Bristol-Myers Squibb (20)  ·  National Cancer Institute (NCI) (16)  ·  M.D. Anderson Cancer Center (15)  ·  Merck Sharp & Dohme LLC (12)  ·  Hoffmann-La Roche (9)  ·  Beth Israel Deaconess Medical Center (8)  ·  University Health Network, Toronto (8)  ·  Memorial Sloan Kettering Cancer Center (7)  ·  Abramson Cancer Center at Penn Medicine (6)  ·  Argos Therapeutics (6)  ·  Ipsen (6)  ·  Radboud University Medical Center (6)  ·  RenJi Hospital (6)  ·  University of Texas Southwestern Medical Center (6)

Countries

United States (353)  ·  China (74)  ·  Canada (57)  ·  United Kingdom (56)  ·  Spain (52)  ·  France (48)  ·  Australia (46)  ·  Italy (46)  ·  Germany (38)  ·  South Korea (38)  ·  Netherlands (35)  ·  Poland (28)  ·  Belgium (23)  ·  Russia (21)  ·  Czechia (19)

Top investigators

Eric Jonasch, MD (5)  ·  Harriet Kluger, MD (3)  ·  Roberto Pili, MD (3)  ·  Wenxin Xu, MD (3)  ·  Bradley McGregor, MD (2)

Results publications

PMID 37146227, PMID 31401903, PMID 33058158, PMID 33526329, PMID 41969229, PMID 27238653, PMID 27279544, PMID 28410911, PMID 29439857, PMID 11923603, PMID 12136861, PMID 14532767, PMID 15076282, PMID 15814627, PMID 17113889, PMID 17804777, PMID 17876014, PMID 17893567, PMID 18295861, PMID 18602688, PMID 18632142, PMID 18803341, PMID 19222048, PMID 19434703, PMID 20179242, PMID 20633979, PMID 21146917, PMID 21277078, PMID 21354816, PMID 21741163, PMID 21858552, PMID 21917625, PMID 21958521, PMID 22045104, PMID 22105611, PMID 22285180, PMID 22461641, PMID 22658127, PMID 22918393, PMID 23180114, PMID 23213092, PMID 23665131, PMID 23726267, PMID 23747347, PMID 23787357, PMID 23937616, PMID 24013181, PMID 24063860, PMID 24089446, PMID 24297945

NIH funding

2016 (7), 2018 (6), 2023 (5), 2017 (4), 2008 (3), 2015 (3), P30CA033572 (2), U10CA180886 (2), 2004 (1), 2009 (1), 2014 (1), 2019 (1), 2025 (1), 5UG1CA189824-08 (1), F31CA239330 (1)